Risk of Using Sodium Valproate in Female Patients

Post date: Feb 16, 2017 3:37:21 AM

26th January 2017 (Circular NO. SP PPUM: 34/2017):

The National Pharmaceutical Regulatory Agency (NPRA) has issued a guide on the use of Valproate in female patients due to the risk of abnormal pregnancy outcomes.

Please click here to read the "Guide for Healthcare Profesionals- Medicines Related to Valproate: Updates on the Risk of Abnormal Pregnancy Outcomes".